FindTrial
Sign In

Metabonomics study of irritable bowel syndrome

Metabonomics study of irritable bowel syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020072
Enrollment
Unknown
Registered
2018-12-13
Start date
2014-01-01
Completion date
Unknown
Last updated
2018-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IBS

Interventions

Gold Standard:Clinical presentations: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorders (FGIDs), which is characterized by chronic or recurrent abdominal pain, abdominal
Index test:Urinary&#32
Metabolite&#32
Biomarkers&#32

Sponsors

Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. IBS with diarrhea; 2. healthy volunteers (without taking any drugs or supplements); 3. Aged > 18 years old.

Exclusion criteria

Exclusion criteria: 1. patients with active gastrointestinal bleeding; 2. Patients who refuse to participate in this clinical trial; 3. Patients considered by the attending physician not suitable for participating in this clinical trial.

Design outcomes

Primary

MeasureTime frame
metabolomics;—

Countries

China

Contacts

Public ContactQihong Yu

Changhai Hospital Affiliated to the Second Military Medical University

yuqihong1979@163.com+86 15801872948

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 22, 2026